1 One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. D.N. Podlekareva, A. Schultze, A. Panteleev, A.M. Skrahina, J.M. Miro,  A. Rakhmanova†, H. Furrer, R.F Miller, A.M. W. Efsen, M.H. Losso, J. Toibaro, A. Vassilenko, E. Girardi, J.D. Lundgren, A. Mocroft, F.A. Post, O. Kirk, on behalf of the TB:HIV study group in EuroCoord.
AIDS. 2017;31(3):375-384. Abstract

2 Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
Annals of Internal Medicine. 2017;166(1):9-17. abstract

3 Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.  Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. 
HIV Medicine. 2017;18(1):33-44. abstract

4 Combination antiretroviral therapy and cancer risk. AH Borges
Current Opinion in HIV & AIDS. 2017;12(1):12-19. Abstract

5 Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. J O'Connor, MJ Vjecha, AN Phillips, B Angus, D Cooper, B Grinsztejn, G Lopardo, S Das, R Wood, A Wilkin, H Klinker, P Kantipong, KL Klingman, D Jilich, E Herieka, E Denning, I Abubakar, F Gordin, JD Lundgren; INSIGHT START study group.
Lancet HIV. 2017. pii: S2352-3018(16)30216-8. Abstract

6 Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, A Pikis, RR Razonable, V Miller, PD Griffiths; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum.
Clinical Infectious Diseases. 20171;64(1):87-91.Abstract

7 An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. 
F Nakagawa, V Delpech, J Albert, A Alioum, D Bezemer, M Cortina-Borja, AE Brown, V Cambiano, C Campbell, D Costagliola, A de Luca, R Kouyos, R Lodwick, JD Lundgren, N Pantazis, C Smith, V Supervie, P Tookey, G Touloumi, Zh Yin, A van Sighem, AN Phillips
AIDS. 2017;31(3):417-425. Abstract 8 Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. M Casadellà; A Cozzi-Lepri; A Phillips; M Noguera-Julian; M Bickel; D Sedlacek; K Zilmer; B Clotet; JD Lundgren; R Paredes, on behalf of EuroSIDA in EuroCoord.
PLoS One. 2017;12(1):e0166613. abstract

9 Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Positive Patients? Peters L, Cozzi-Lepri A; Hepatitis C Working Group for the Collaboration of Observational HIV Research Europe (COHERE) in EuroCoord.
AIDS. 2017;31(5):661-668.  abstract

10 Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. 
HIV Med. 2017;18(3):171-180. abstract

11 Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AR Lifson, B Grund, EM Gardner, R Kaplan, E Denning, N Engen, CL Carey, F Chen, S Dao, E Florence, J Sanz, S Emery; INSIGHT START Study Group.
AIDS. 2017;31(7):953-963. Abstract

12 Late presentation of chronic viral hepatitis for medical care: a consensus definition. S Mauss, S Pol, M Buti , E Duffell, C Gore, JV Lazarus ,HL  der Grient, J Lundgren, A Mozalevskis, D Raben, E Schatz, S Wiktor, JK Rockstroh; European consensus working group on late presentation for Viral Hepatitis Care.
BMC Medicine 2017; 15(1):92 abstract

13 Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholc L, Kyselyova G, Lungren JD, Mocroft A; for EuroSIDA.
Clin Infect Dis. 2017;64(10):1413-1421. abstract

14 Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner,  D Duprez, S Emery, B Gazzard, J Gordin, G Grandits, AN Phillips, S Schwarze, EZ Soliman, SA Spector, G Tambussi, J Lundgren; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.
Journal of the American Heart Association 2017; 6(5). Abstract 

15 Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. TS Itenov, JU Jensen, SR Ostrowski, PI Johansson, KM Thormar, JD Lundgren, MH Bestle; “Procalcitonin And Survival Study” study group.
Shock 2017, 47(6) 696-701. Abstract

16 Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. JD Kowalska, C Oprea, S de Witt, A Pozniak, D Gökengin, M Youle,JD Lundgren, A Horban; ECEE Network Group.
HIV Medicine 2017, 18(5): 370-375. Abstract

17 Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. E Lord, AJ Stockdale, R Malek, C Rae, I Sperle, D Raben, A Freedman, D Churchill, J Lundgren, AK Sullivan; British Association of Sexual Health HIV (BASHH)/British HIV Association (BHIVA) guideline review group for the Optimising Testing and Linkage to Care for HIV across Europe (OptTEST) project by HIV in Europeb.
HIV Medicine 2017; 18(4): 300-304. Abstract

18 Hepatitis C virus (HCV) RNA profiles among chronic HIV/HCV-coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in nine individuals. D Grint, E Tedaldi, L Peters, A Mocroft, B Edlin,S Gallien, H Klinker, C Boesecke, P Kokordelis, JK Rockstroh.
HIV Medicine 2017, 18(6):430-434. Abstract

19 Small airway dysfunction in well-treated never-smoking HIV-infected individuals. A Ronit, IH Mathiesen, M Gelpi, T Benfield, J Gerstoft , T Pressler, A Christiansen, J Lundgren, J Vestbo, S Dam Nielsen.
European Respiratory Journal 2017; 2;49(3). Abstract

20 The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. NE Wareham, JD Lundgren, C Da Cunha-Bang, F Gustafsson, M Iversen, HH Johannesen, A Kjær, A Rasmussen, H Sengeløv, SS Sørensen, BM Fischer.
European Journal of Nuclear Medicine and Molecular Imaging 2017;44(3):421-431. Abstract

21 The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.
AIDS. 2016;30(17):2659-2663. Abstract

22 Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Chêne G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Moller N, Raben D, Haerry D, Egger M, Weller I, De Wit S.
Int J Epidemiol. 2017;1;46(3):797-797n. abstract

23 Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. JF Hoy, B Grund, M Roediger, AV Schwartz, J Shepherd, A Avihingsanon, S Badal-Faesen, S de Wit, S Jacoby , A La Rosa, S Pujari, M Schechter, D White, NW Engen, K Ensrud, PD Aagaard, Carr A14; INSIGHT START Bone Mineral Density Substudy Group.
J Bone Miner Res. 2017;32(9):1945-1955. Abstract

24 Are we successfully managing cardiovascular disease in people living with HIV? CI Hatleberg, JD Lundgren, L Ryom.
Curr Opin HIV AIDS. 2017;12(6):594-603. Abstract 

25 Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. MA Boyd, A Mocroft, L Ryom, AD Monforte, C Sabin , WM El-Sadr,  CIHatleberg, S De Wit, R Weber, E Fontas, A Phillips, F Bonnet, P Reiss, J Lundgren, M Law.
PLoS Med. 2017;14(11):e1002424. Abstract

26 Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. DE Dwyer, R Lynfield, MH Losso, RT Davey, A Cozzi-Lepri, D Wentworth, TM Uyeki, F Gordin, B Angus, T Qvist, S Emery, J Lundgren, JD Neaton; INSIGHT Influenza Study Group.
Open Forum Infect Dis; 2017; 4(4):ofx212. Abstract

27 Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable? C Ekenberg, IP Lodding, NE Wareham, SS Sørensen, H Sengeløv, F Gustafsson, A Rasmussen, M Perch, JD Lundgren, M Helleberg
Eur J Clin Microbiol Infect Dis. 2017;36(12):2391-2398. Abstract

28 Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. JR Castillo-Mancilla, AN Phillips, JD Neaton, J Neuhaus, S Collins, S Mannheimer, S Pett, V Touzeau-Römer, MN Polizzotto, JD. Lundgren and
EM Gardner for the INSIGHT SMART Study Group
Open Forum Infectious Diseases, 2018; 5(1), ofx275. Abstract

29 Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.. L Ryom, A Mocroft, O Kirk, P Reiss, M Ross, C Smith, O Moranne, P Morlat, CA Fux; C Sabin, A Phillips, M Law, JD Lundgren. On behalf of the D:A:D Study group.
AIDS. 2017;31(9):1261-1270.  Abstract

30 HIV testing in Europe: Evaluating the impact, added value, relevance and usability of the European Centre for Disease Prevention and Control (ECDC)'s 2010 HIV testing guidance. AK Sullivan, I Sperle, D Raben, AJ Amato-Gauci, JD Lundgren, Y Yazdanpanah, SF Jakobsen, L Tavoschi
Euro Surveill. 2017;22(48). Abstract

31  Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe. A Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, M Backmund, B Bruggmann, O Dalgard, C Seguin-Devaux, R Flisiak, GR Foster, L Gheorghe, D Goldberg, I Goulis, M Hickman, P  Hoffmann, L Jancorienė, P Jarcuska, M Kåberg, LG Kostrikis, M Makara, M Maimets, RT Marinho, M Matičič, S Norris, S Ólafsson, A Øvrehus, JM Pawlotsky, J Pocock, G Robaeys, C Roncero, M Simonova, J Sperl, M Tait, I Tolmane, S Tomaselli, M van der Valk, A Vince, GJ Dore, JV Lazarus, and J Grebely.
Lancet Gastro Hep, 2017. Abstract

32  Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. JV Lazarus, I Sperle, K Safreed-Harmon, C Gore, B Cebolla, A Spina..
BMC Public Health, July 2017. Abstract

33  Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. L Wiessing, M Ferri, V Běláčková , P Carrieri, SR Friedman, C Folch, K Dolan, B Galvin, P Vickerman, JV Lazarus, V Mravčík, M Kretzschmar, V Sypsa, A Sarasa-Renedo, A Uusküla, D Paraskevis, L Mendão, D Rossi, N van Gelder, I Mitcheson, L Paoli, CD Gomez, M Milhet, N Dascalu, J Knight, G Hay, E Kalamara, R Simon; EUBEST working group, C Comiskey, C Rossi,P Griffiths. Harm Reduct J. 2017 Apr 22;14(1):19. Abstract

34  Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. JV Lazarus, K Safreed-Harmon, SR Stumo, M Jauffret-Roustide, M Maticic, T Reic, E Schatz, J Tallada, M Harris, on behalf of the Hep-CORE Study Group.
Int J Drug Policy, 2017; 14;47-50. Abstract

35  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. J Grebely, J Bruneau, JV Lazarus, J Byrne, L Crooks, O Dalgard, P Bruggmann, C Treloar, M Hickman, M Hellard, T Roberts, L Crooks, H Midgard, S Larney, L Degenhardt, H Alho, J Byrne, J Dillon, JJ Feld, G Foster, D Goldberg, J Khalsa, A Lloyd, J  Reimer, G Robaeys, M Torrens, N Wright, B Norton, A Litwin, G Dore, on behalf of the International Network on Hepatitis in Substance Users.
Int J Drug Policy, 2017, 47: 51-60. Abstract

36  Associations between national viral hepatitis policies/programmes and country-level socioeconomic factors: a sub-analysis of data from the 2013 WHO viral hepatitis policy report. JV Lazarus, I Sperle, K Safreed-Harmon, C Gore, B Cebolla, A Spina.
BMC Public Health, 2017, 18(1):16. Abstract

37 Micro-elimination – a path to global elimination of hepatitis C. JV Lazarus, SZ Wiktor, M Colombo, M Thursz..
Journal of Hepatology, July 2017; 67(4): 665-666. Abstract

38 Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. L Wiessing, M Ferri, V Běláčková, P Carrieri, SR Friedman, C Folch, K Dolan, B Galvin, P Vickerman, JV Lazarus, V Mravčík, M Kretzschmar, V Sypsa, A Sarasa-Renedo, A Uusküla, D Paraskevis, L Mendão, D Rossi, N van Gelder, L Mitcheson, L Paoli, CD Gomez, M Milhet, N Dascalu, J Knight, G Hay, E Kalamara, R Simon; EUBEST working group, C Comiskey, C Rossi, P Griffiths. 
Harm Reduct J. 2017;14(1):19. Abstract

39 Commentary on Trias-Llimos et al. (2017): Birth cohort research— an essential tool to guide public health interventions. JV Lazarus, D Bromberg.
Addiction, 2017; 112(2):259-260. Abstract

40 Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013. M Molinier, C Brouard, P Sogni, F Barin, JV Lazarus, X Pascal, J Pillonel, M Jauffret-Roustide and the ANRS Coquelicot Study-Group.
Epidemiology and Infection, 2017 :1-11. Abstract